Anne‐Claire Hardy‐Bessard

Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial

M. Spielmann, Henri Roché, T. Delozier et al. · Journal of Clinical Oncology · 2009 · 298 citations

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

François‐Clément Bidard, Anne‐Claire Hardy‐Bessard, Florence Dalenc et al. · The Lancet Oncology · 2022 · 285 citations

Breast Oncology, Esr1 Mutation, Endocrine-related Cancer +10

Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO

Jacobus Pfisterer, B. Weber, Rainer Kimmig et al. · JNCI Journal of the National Cancer Institute · 2006 · 208 citations

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García et al. · The Lancet · 2023 · 175 citations

Oncology, Cervical Cancer, Metronomic Therapy +6

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard et al. · European Journal of Cancer · 2020 · 163 citations · Full text

Solid Cancer Patients, Cancer Epidemiology, Disease Risk Assessment +12